文献速递姑息放疗与转移瘤放疗物理与技术

横纹肌肉瘤质子束治疗后的疾病控制与失败模式

Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-01

肿瘤>5 cm及化疗开始至放疗间隔≥13周预测局部控制更差,支持对>5 cm肿瘤进行剂量递增的前瞻性研究,并质疑局部治疗的最佳时机。

核心结论

  • 质子束治疗可提供与既往光子放疗研究相当的局部控制。
  • 较大肿瘤及延迟放疗者局部控制、无进展生存和总生存均更差。

研究设计与样本

  • 所有患者接受化疗联合质子束治疗,回顾人口学、临床特征及治疗相关结局。

主要发现

  • 中位随访4年,4年总生存率71%,4年无进展生存率63%。
  • 30例(32%)复发,其中13%为局部失败;4年局部控制率总体85%。

关键数值与推荐

  • 中位肿瘤大小4.1 cm(范围1.0-16.5 cm),33例(35%)原发肿瘤>5 cm。
  • 中位环磷酰胺等效剂量14.4 g/m²(范围0-30.8 g/m²)。
  • 化疗开始至放疗开始中位时间13周(范围1-58周)。

临床怎么用

  • 质子束治疗可作为横纹肌肉瘤局部治疗选择,局部控制与光子放疗相当。
  • 对>5 cm肿瘤应考虑剂量递增策略,并关注局部治疗时机。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pediatric patients with rhabdomyosarcoma (RMS) are treated with multimodal therapy, often with radiation therapy (RT) as part of local therapy. We report on the efficacy and patterns of failure after proton beam therapy (PBT) for RMS. METHODS AND MATERIALS: Between January 2006 and February 2017, patients with RMS were enrolled in a prospective institutional review board-approved registry protocol for pediatric patients undergoing PBT. Demographics, clinical characteristics, and treatment related outcomes were reviewed. RESULTS: Ninety-four RMS patients were treated with a combination of chemotherapy (CT) and PBT. The majority of patients had head and neck (49%) and genitourinary (30%) primaries. Median tumor size was 4.1 cm (range, 1.0-16.5 cm); 33 patients (35%) had primary tumors >5 cm. Median cyclophosphamide equivalent dose was 14.4 g/m2 (range, 0-30.8 g/m2). Median time from CT initiation to RT initiation was 13 weeks (range, 1-58 weeks). With median follow-up of 4 years, 4-year overall survival (OS) was 71%, and 4-year progression-free survival (PFS) was 63%. Thirty patients (32%) experienced relapse (13% with local failure [LF]). Four-year local control (LC) was 85% overall; 4-year LC rates were 100% for low-risk, 85% for intermediate-risk, and 55% for high-risk patients (P = .02). Tumor size predicted LC (P = .007), with 7% versus 33% LF rate by tumor size (≤5 cm vs >5 cm). Delayed RT delivery (≥13 weeks from initiation of CT) predicted worse LC (P = .01). Increased tumor size predicted both inferior PFS (P = .02) and OS (P = .01). Delayed RT delivery predicted both inferior PFS (P = .04) and OS (P = .03). CONCLUSIONS: PBT provides LC comparable to prior studies using photon RT. Inferior LC, PFS, and OS rates were observed for patients with larger tumors and those treated with delayed RT. This finding supports ongoing prospective efforts to dose-escalate treatment of tumors >5 cm; however, these data call into question the optimal timing of local therapy, particularly for patients treated with reduced-dose cyclophosphamide.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Buszek SM, Ludmir EB, Grosshans DR, et al. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021. PMID: 33516439. doi:10.1016/j.ijrobp.2020.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。